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 Diabetic retinopathy (DR), one of the most important mi-
crovascular complications in both forms of diabetes mellitus,
has been considered a major cause of visual impairment world-
wide [1-4].
Many biochemical mechanisms have been proposed to
explain the structural and functional abnormalities associated
with overexposure of the vascular tissues to hyperglycemia
including advanced glycation end products (AGEs), increase
in aldose reductase (AR) activity, free radicals acummulation
(reactive oxygen intermediate pathway, ROI), resulting in oxi-
dative stress and protein-kinase C activation (PKC) through
diacylglycerol accumulation (DAG). All these pathways, ei-
ther directly or indirectly, are associated with the production
and signaling of vascular endothelial growth factor (VEGF),
contributing to the development of neovessels in DR [5,6].
Although diabetes duration and inadequate glycemic con-
trol are important risk factors in the development of DR, ge-
netic factors may play a significant role in the pathogenesis of
this complication [7]. Some genes have been specifically im-
plicated in the etiology of DR, including the ones associated
with glycosylation, immune response, collagen formation,
platelet adhesion and aggregation, and the polyol pathway [8].
AR, the first enzyme of the polyol pathway, probably plays
an important role in the pathogenesis of the long-term com-
plications of diabetes by means of alterations that result from
sorbitol increase and myo-inositol reduction [7]. AR is respon-
sible for the conversion of glucose to sorbitol, which is then
converted into fructose by the enzyme sorbitol dehydrogenase
(SORD). During the exposition to hyperglycemia, there is an
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Purpose: Diabetic retinopathy (DR) is one of the most important microvascular complications in both type 1 and type 2
diabetes. In Brazil, its proliferative form is the second cause of irreversible blindness among adults of working age.
Despite the strong association of DR with disease duration and degree of chronic hyperglycemia, genetic predisposition
has been recognized as a possible trigger in the development of this complication. Recent studies have demonstrated that
the development of DR in patients with type 1 diabetes is associated with the occurrence of polymorphisms at the 5'-end
of the aldose reductase gene (ALR2). There are no reports investigating these polymorphisms in type 1 diabetes Brazilian
patients. The aim of this study was to investigate the relationship between the AC(n) repeat and C(-106)T polymorphisms
of the ALR2 gene with the susceptibility to the development of DR in Brazilian patients with type 1 diabetes.
Methods: We selected 64 patients who had diabetes for at least 10 years from Santa Casa de São Paulo and State Univer-
sity of Campinas. The study group was divided into the following: Group 1, patients with no evidence of diabetic retinopa-
thy; group 2, patients with nonproliferative diabetic retinopathy (NPDR); and group 3, patients with proliferative diabetic
retinopathy (PDR), confirmed by fundoscopy. The AC(n) microsatellite region was evaluated through polymerase chain
reaction (PCR) and automated genotyping and the C(-106)T substitution through polymerase chain reaction/restriction
fragment length polymorphism (RFLP).
Results: When each allele of the AC(n) polymorphism was evaluated, the Z allele (24 repeats) was significantly associ-
ated with the development of PDR (p=0.014). The C allele of the C(-106)T substitution wasn’t associated with the suscep-
tibility to this microvascular complication (p=0.153). When the Z and C allele were concomitantly evaluated regarding
their presence or absence a positive correlation was observed for the presence of both alleles and the development of PDR.
Conclusions: In our sample of Brazilian patients with type 1 diabetes, the presence of the AC(n) polymorphism Z allele
may be considered a risk factor for the development of PDR. The C allele of the C(-106)T polymorphism, in association
with the Z allele, also increased the risk for the development of PDR, but when it was analyzed by itself there was no
association with the complication.
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740enhanced flux of AR (increased enzyme activity and expres-
sion of the aldose reductase gene-ALR2) and a reduced flux of
SORD. This imbalance results in the accumulation of sorbi-
tol, which leads to several abnormalities in cellular metabo-
lism and hence contributes to the development of diabetic
microvascular complications [9,10].
Different reports suggest that the AC(n) dinucleotide poly-
morphism, located 2.1 kb upstream the transcription start site
of ALR2, is associated with the susceptibitily to diabetic com-
plications as nephropathy and retinopathy [7,9-12]. Recently
Cheung and co-workers, through the study of ALR2 gene
knockout mice, suggested that AR is responsible for the early
events in the pathogenesis of diabetic retinopathy, triggering
a cascade of retinal lesions that would lead to
neovascularization [13].
In addition, another polymorphism, the C-(106)T in the
promoter region of ALR2, has also been correlated with the
susceptibility to the development of DR, acting alone or com-
bined with the AC(n) polymorphism [7,9,10,14].
To the best of our knowledge, there are four studies re-
lated to these polymorphisms in ALR2 in Latin America. Two
studies were performed by Olmos and colleagues in Chilean
type 2 diabetic patients, who found a positive correlation be-
tween the Z-2 allele of the AC(n) polymorphism and a faster
progression of retinopathy when compared with patients who
harbored other alleles [12] and also an association between
the CC genotype of the C(-106)T polymorphism with the de-
velopment of retinopathy [15]. The first study performed by
Santos and co-workers analyzed a specif type 2 diabetic popu-
lation in the south Brazil, which was denominated Euro-Bra-
zilian. They reported no correlation between the C(-106)T
polymorphism with DR [14]. In a recent study the same group
evaluated a greater number of Caucasian-Brazilians as well
as African-Brazilians DM2 patients, demonstrating that among
the Caucasian-Brazilian patients the CC genotype was inde-
pendently associated with an increased risk of PDR [16].
The aim of this study was to investigate a possible corre-
lation between the AC(n) and C(-106)T polymorphisms and
diabetic retinopathy in DM1 Brazilian patients. This popula-
tion is characterized by an ethnic admixture and there is no
study that evaluates these two ALR2 structural alterations in
DM1 patients from Brazil.
METHODS
Patients:  The study group was constituted by 64 Brazilian
patients with diabetes mellitus type 1, with at least 10 years of
disease. Thirty five were selected in the pediatric and adult
endocrinology service, Irmandade da Santa Casa de
Misericórdia de São Paulo, and 29 in the adult endocrinology
service, State University of Campinas, Unicamp, during a 2
year period, from June 2003 to April 2005. This study ad-
hered to the tenets of the Declaration of Helsinki and received
the approval of Ethics Committee of both institutions. All pa-
tients signed an informed consent.
Patients underwent a comprehensive clinical and oph-
thalmic evaluation. The following demographic, clinical and
laboratory information was documented for each subject: mean
age, sex, diabetes, age of onset, and duration, presence of hy-
pertension (blood pressure was corrected according to sex and
age [17]), body mass index Z score (ZBMI; Growth Analyser
3 Software, Version 3.0, Dutch Growth Foundation), presence
of chronic complications (neuropathy and proteinuria), fun-
doscopy, average glycated HbA and insuline dosage.
Ophthalmic evaluation was performed by indirect fundo-
scopy and biomicroscopy and, in case of abnormalities, docu-
mented by retinography. In the presence of diabetic retinopa-
thy, it was classified as non-proliferative diabetic retinopathy
(NPDR) and proliferative diabetic retinopathy (PDR) [18]. The
following clinical and laboratory parameters were compared
according to the status of retinopathy: mean age, diabetes age
of onset, duration of disease, ZBMI, presence of hyperten-
sion, average glycated HbA and insulin dosage.
Controls:  The normal control group was composed of 55
healthy blood donors who had no family history of diabetes.
They were recruited from Hemocentro, Santa Casa de São
Paulo, and have an ethnic background and geographic distri-
bution similar to that of the study group.
AC(n) polymorphism:  Genomic DNA was isolated from
peripheral leukocyte by standard methods [19]. Amplification
of a 138 bp fragment (Z allele), which includes the repetition
region AC, located 2.1 kb upstream the ALR2 gene was per-
formed, using a modification of the method reported by Ko
and colleagues [11]. The forward primer was marked at the 5'
end with the FAM fluorescent marker (Invitrogen™ Life Tech-
nologies, Carlsbad, CA).
After the amplification, 1 µl of the PCR product, diluted
1:7 in ddH2O, was mixed with 0.5 µl of the internal molecular
weight marker (GeneScan™ 500 ROX™ Size Standard, Ap-
plied Biosystems, Warrington, UK) and 23.5 µl of deionized
formamide (Hi-Di™ Formamide, Applied Biosystems, Fos-
ter City, CA). This mixture was denatured at 95 °C for 2 min
and kept on ice until the submission to capillary electrophore-
sis in the automatic DNA analyzer ABI PRISM 310 (Applied
Biosystems), at 60 °C for 20 min per sample. Results were
analyzed through the GeneScan software (ABI Prism®
GeneScan Analysis Software version 3.7 for Windows NT®
Platform, Applied Biosystems) and Genotyper (ABI Prism®
Genotyper® 307 NT Software, Applied Biosystems).
In order to confirm the number of repetitions and hence estab-
lish a reference for genotyping, patients who presented the
alleles in homozygosity were selected and their DNA samples
submitted to sequencing reactions, using the following prim-
ers: forward 5'-GGA CTA AGG GAA GGC AAG TG-3' and
reverse 5'-CCT TCA ATG GAA TCC TCC TG-3' (Genbank
accession number U72619). PCR products were directly se-
quenced through the big dye terminator cycle sequencing ready
reaction kit, version 3.1 (Applied Biosystems, Foster City, CA),
according to manufacturer’s instructions and electrophoresed
in a DNA automatic analyzer (ABI Prism 310; Applied
Biosystems, Foster City, CA). The sequences were searched
for similarities by using the BLAST search algorithm avail-
able at BLAST website.
C(-106)T polymorphism:  A fragment of the ALR2 gene
promoter region containing the C(-106)T polymorphism was
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741amplified by PCR. The following pair of primers was selected:
Forward-5'-TTC GCT TTC CCA CCA GAT AC-3', between
nucleotides -255 and -235 and reverse-5'-CGC CGT TGT TGA
GCA GGA GAC-3', between nucleotides 50 and 71, resulting
in the amplification of a 326 bp fragment. Samples were sub-
jected to 35 cycles of amplification, each consisting of dena-
turation at 95 °C for 1 min, annealing at 57 °C for 1 min, and
extension at 72 °C for 1 min with a final extension at 72 °C
for 7 min (GeneAmp® PCR System 9700, Applied
Biosystems) [7,20].
In order to detect the C(-106)T polymorphism, the 326
bp fragment was digested with the restriction endonuclease
BfaI (New England BioLabs, MA), once this substitution cre-
ates a new restriction site to the enzyme. The homozygous
CC individuals presented two fragments of 234 bp and 92 bp;
the homozygous TT individuals presented three fragments of
175 bp, 92 bp, and 59 bp and finally, the heterozygous CT
individuals presented four fragments of 234 bp, 175 bp, 92
bp, and 59 bp [7].
Statistical analysis:  The descriptive analysis of demo-
graphic, clinical, diagnosis and molecular data of our patients
was performed.
Based on fundoscopy findings, patients were divided into
NORMAL and DR. Genotypes and allelic frequency of the
AC(n) and C(-106)T polymorphisms were compared accord-
ing to the following stratifications: 1. Normal X DR, 2. Nor-
mal X NPDR X PDR, 3. Normal X PDR, and 4. NPDR X
PDR.
The data were loaded in the Statistical Program for the
Social Sciences (SPSS, version 13.0, SPSS Inc., Chicago, IL).
Either the Χ-square test or the Fisher’s exact test was used for
categorical variables. The Mann-Whitney Test was used for
continuous variables. p-values <0.05 were considered to be
statistically significant.
RESULTS
 The mean age of the studied patients was 26.72±10.52
years, ranging from 12.10-57 years. Forty-three patients were
female (67.2%) and, in relation to the skin color, 47 were white
(73.4%), five black (7.8%), and 12 mulatto (18.8%). As stated
at both introduction and discussion, the Brazilian population
is highly miscigenated, making it difficult to establish an
ethnicity. In this study, skin color was arrived at based on the
observation of the researchers. The classification of white,
black, and mulatto was determined not only by the skin color,
but also by the observation of other characteristics, such as
hair, lips, and nose shape. The predominant genotype for the
AC(n) polymorphism was Z/Z-2 (26.6%), followed by Z/Z+2
(12.5%), and Z-2/Z-2 (12.5%), totalizing 18 different geno-
types observed. The most common alleles of this polymor-
phism were Z-2 (35.2%), Z (35.2%), and Z+2 (15.6%). The
distribution of the alleles of the AC (n) polymorphism in rela-
tion to the classification of fundoscopy as well as in normal
controls is depicted in Table 1. The most common genotype
of the C-106T polymorphism was CT corresponding to 50%
of the cases, followed by CC, corresponding to 40.3% of the
analyzed cases. In relation to the distribution of the alleles of
this polymorphism, allele C, encompassing 65.3% of the cases,
was more frequent than allele T (34.7%).
The frequencies of both AC(n) and C(-106)T genotypes
in our normal control population were in Hardy-Weinberg equi-
librium. Ten alleles were observed for the AC(n) polymor-
phism, ranging from Z-16 to Z+12, with Z (43.6%) and Z-2
(34.6%) being the most frequent ones. For the C(-106)T poly-
morphism, allele C was present in 67.9% of the subjects and
allele T in 32.1%.
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TABLE 1. ALLELIC FREQUENCY OF AC(N) REPEATS IN DIABETIC
PATIENTS AND NORMAL CONTROLS
         Diabetes mellitus type 1 patients
         ---------------------------------
         Normal (%)   NPDR (%)    PDR (%)    Controls
Allele     n=66         n=32        n=30     (%) n=110
------   ----------   ---------   ---------   ---------
Z+12     0 (0.0)      0 (0.0)     0 (0.0)     2 (1.8)
Z+6      2 (3.0)      1 (3.1)     0 (0.0)     2 (1.8)
Z+4      4 (6.1)      1 (3.1)     1 (3.3)     7 (6.4)
Z+2      13 (19.7)    5 (15.6)    2 (6.7)     8 (7.3)
Z        20 (30.3)    8 (25.0)    17 (56.7)   48 (43.6)
Z-2      23 (34.8)    14 (43.8)   8 (26.7)    38 (34.6)
Z-4      3 (4.5)      3 (9.4)     1 (3.3)     2 (1.8)
Z-6      1 (1.5)      0 (0.0)     1 (3.3)     1 (0.9)
Z-12     0 (0.0)      0 (0.0)     0 (0.0)     1 (0.9)
Z-16     0 (0.0)      0 (0.0)     0 (0.0)     1 (0.9)
NPDR represents nonproliferative diabetic retinopathy; PDR repre-
sents proliferative diabetic retinopathy; n represents number of alle-
les.
TABLE 2. EVALUATION OF THE OF THE AC(N) POLYMORPHISM Z
ALLELE IN RELATION TO DIABETIC RETINOPATHY, BASED ON THE
CLASSIFICATION NORMAL AND PROLIFERATIVE DIABETIC RETINOPATHY
             Fundoscopy classification
           ------------------------------
Allele Z   PDR (%) n=30   Normal (%) n=66
--------   ------------   ---------------
Present     17 (56.7)       20 (30.3)
Absent      13 (43.3)       46 (69.7)
χ-square test: p=0.014; odds ratio=3.01 (1.23-7.34, confidence in-
terval=95%). PDR represents proliferative diabetic retinopathy n rep-
resents number of alleles=96.
TABLE 3. EVALUATION OF THE OF THE AC(N) POLYMORPHISM Z
ALLELE IN RELATION TO DIABETIC RETINOPATHY, BASED ON THE
CLASSIFICATION OF NONPROLIFERATIVE DIABETIC RETINOPATHY AND
PROLIFERATIVE DIABETIC RETINOPATHY.
             Fundoscopy classification
           -----------------------------
Allele Z   PDR (%) n=30   NPDR (%) n=32
--------   ------------   --------------
Present     17 (56.7)       8 (25.0)
Absent      13 (43.3)       24 (75.0)
χ-square test: p=0.011 odds ratio=3.92 (1.34-11.53, confidence in-
terval=95%). PDR represents proliferative diabetic retinopathy,
NPDR represents nonproliferative diabetic retinopathy, and n repre-
sents number of alleles=62.
742Among the clinical and laboratory parameters evaluated,
only age and diabetes’ duration were different between pa-
tients with and without DR. Both parameters were higher in
the group with DR. Average patients age was 24.16±9.59 years
in the group without DR and 29.44±10.93 years in the group
with DR (p=0.036). Duration of diabetes was 14.43±3.81 years
in patients without DR and 17.87±6.28 years in patients with
DR (p=0.015).
AC(n) polymorphism:  No association was observed be-
tween the genotypes of the AC(n) polymorphism and DR de-
velopment, when these were evaluated according to the groups’
stratifications. On the other hand, when each allele was evalu-
ated in relation to fundoscopy, only the Z allele appeared to be
significantly associated with the presence of PDR, with a risk
greater than three times for individuals harboring this allele
(Normal X PDR, risk = 3.01 and NPDR X PDR, risk=3.92).
There was no difference regarding the classification Normal
X DR (p=0.170). Table 2 and Table 3 show patients distribu-
tion according to the presence or absence of the Z allele and
the development of PDR. There was no difference in the du-
ration of the disease in relation to the presence or absence of
the Z allele (p=0.053). Once the Z allele was associated with
the development of PDR, combined genotypes including this
allele (Z) and any other allele with exception to Z (X) were
compared in eye fundoscopy results (ZZ x ZX, ZZ x XX, and
ZX x XX), confirming the susceptibility to the development
of this complication in ZZ individuals in relation to XX indi-
viduals (Table 4). The average duration of disease for patients
with the ZZ, ZX and XX alleles was 14.43±3.95, 17.79±6.07,
and 16.10±5.40, respectively.
C-(106)T polymorphism:  In relation to the C(-106)T poly-
morphism, we found no association between genotypes and
the susceptibility to the development of DR (p = 0.316). How-
ever, our data show that among the 14 patients with PDR, no
one presented with the TT genotype (Table 5). Also, when the
alleles were analyzed, we observed no correlation between
these and susceptibility or protection to the development of
the disease (p=0.153).
Haplotype AC(n)/C(-106)T:  When patients were analyzed
in relation to the presence of the C and Z alleles concomi-
tantly and the development of DR, it was observed that the
presence of both alleles (allele C + allele Z) represents a ten-
dency to the development of PDR (Normal X PDR, risk of
PDR=5.65; Table 6). However, when we analyzed the pres-
ence of C and Z alleles versus only C (p=0.159) and C and Z
alleles versus only Z (p=1,000), we found no statistically sig-
nificant differences between the groups.
DISCUSSION
 It is intriguing that despite good control of blood glucose lev-
els, some diabetic patients develop complications such as
microangiopathies while others remain problem free after a
long period of diabetes. Today there is considerable evidence
that some diabetic complications are influenced not only by
the long exposure to hyperglycemia but also by genetic fac-
tors [8,9,11,12,21].
Aldose reductase gene promoter polymorphisms AC(n)
and C(-106)T have been extensively investigated in different
populations. Some studies have shown that they may lead to
increased mRNA expression of the ALR2 gene and conse-
quently to the accumulation of sorbitol and cellular damage
[21,22].
The most common genotype related to the AC(n) poly-
morphism is represented by 24 dinucleotides AC and denomi-
nated Z [9,11,23,24]. Although results conflict, depending on
the population, most studies correlate the Z-2 allele with com-
plication risk while the Z+2 allele appears to be linked to pro-
tection [7,9-12].
In our population, the Z allele appeared to be significantly
associated with the development of PDR, with a complication
development risk that was three times greater than individu-
als harboring other alleles. This data differ from all other groups
previously studied. It is important to consider that our popula-
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TABLE 4. DISTRIBUTION OF PATIENTS WITHOUT RETINOPATHY AND
WITH PROLIFERATIVE DIABETIC RETINOPATHY, ACCORDING TO THE
AC(N) POLYMORPHISM ZZ GENOTYPE
            Fundoscopy classification
           -----------------------------
Genotype   PDR (%) n=6   Normal (%) n=17
--------   -----------   ---------------
   ZZ       4 (66.7)        2 (11.8)
   XX       2 (33.3)       15 (88.2)
X represents any allele other than Z. Fisher’s exact test is p=0.021.
TABLE 5. DISTRIBUTION OF PATIENTS WITHOUT RETINOPATHY, WITH
NONPROLIFERATIVE DIABETIC RETINOPATHY, AND WITH PROLIFERATIVE
DIABETIC RETINOPATHY, BASED ON THE GENOTYPES OF THE C(-106)T
POLYMORPHISM
                      Fundoscopy classification
           ----------------------------------------------
Genotype   Normal (%) n=33   NPDR (%) n=15   PDR (%) n=14
--------   ---------------   -------------   ------------
   CC        10 (30.30)        8 (53.33)      7 (50.00)
   CT        18 (54.54)        6 (40.00)      7 (50.00)
   TT         5 (15.16)        1 (6.67)       0 (0.00)
χ-square test: p=0.316. NPDR represents nonproliferative diabetic
retinopathy; PDR represents proliferative diabetic retinopathy; n rep-
resents number of patients=62.
TABLE 6. DISTRIBUTION OF PATIENTS WITHOUT RETINOPATHY AND
WITH PROLIFERATIVE DIABETIC RETINOPATHY BASED ON THE PRESENCE
OF THE C ALLELE OF THE C(-106)T POLYMORPHISM AND THE Z
ALLELE OF THE AC(N) POLYMORPHISM
                        Fundoscopy classification
                      ------------------------------
Allele C + Allele Z   PDR (%) n=14   Normal (%) n=33
-------------------   ------------   ---------------
     Present           12 (85.7)        17 (51.5)
     Absent             2 (14.3)        16 (48.5)
χ-square test: p=0.027, odds ratio=5.65 (1.09-29.26, confidence in-
terval=95%). PDR represents proliferative diabetic retinopathy; n
represents number of patients=47.
743tion is ethnically distinct and that there are no previous stud-
ies of this polymorphism in the Brazilian population. In Japa-
nese patients with type 2 diabetes the Z-4 allele may deter-
mine the predisposition to retinopathy [25] while Wang and
coworkers [10] observed that the Z+6 allele may confer a pro-
tective effect. In order to evaluate the existence of a possible
bias due to the greater duration of diabetes in individuals with
diabetic retinopathy, we evaluated the duration of the disease
in the presence and absence of the Z allele. Our analysis showed
that this variable is not statistically different between patients
with and without this allele. However, the p value is too close
to the limit of significance and hence the duration of the dis-
ease could not be excluded as a confounding factor. In con-
trast, the duration of diabetes was greater among patients with
the XX genotype (16.10±5.40) than in individuals with the
ZZ genotype (14.43±3.95).
A more definite relationship can be established between
the Z allele of the AC(n) polymorphism and predisposition to
the development of PDR, by performing gene expression stud-
ies in our population of DM1 patients, as the study conducted
by Shah and colleagues [22].
In the analysis of the genotype of our patients we did not
find correlation with the susceptibility or protection to DR
development, probably due to the small number of patients
for each genotype, as reproduced by previous studies
[12,24,26].
In respect to the C(-106)T polymorphism, many groups
suggest that the presence of the T allele gives some protection
to the development of DR, and the presence of the C allele
raises the susceptibility to the development of this complica-
tion [7,9]. In relation to the functional aspect, Li [21] exam-
ined the possible correlation between the C-(106)T polymor-
phism and the ALR2 gene expression, and found that the pres-
ence of the C allele increases twice mRNA expression.
In the present study, it was not observed any statistical
association based on the genotypes, although no patient with
PDR presented the TT genotype and among 6 individuals with
this genotype, 5 were normal and 1 presented a mild form of
DR. The C allele was not related to DR susceptibility when
analyzed separately, probably due to the size of our sample.
Our findings are similar to the ones described by Santos for
DM2 patients [14].
Kao [7] and Demaine [9] analyzed the (AC)n and C(-
106)T polymorphisms and verified that the C allele in asso-
ciation with the Z-2 allele is related to the development of
DR. When we investigated the effect of the presence and ab-
sence of both polymorphisms in our population, we found a
5.65 times greater tendency for the development of PDR to
individuals who presented both alleles compared to the ones
who didn’t present. We found no increased risk in the devel-
opment of PDR when the presence of C and Z alleles was
compared to the presence of only C or only Z allele.
There are many factors that could explain the association
of the Z allele with PDR in our population. First, populations
evaluated for these polymorphisms are ethnically distinct [7,9-
12,25]. Second, the Z allele could be linked to another sus-
ceptibility gene, acting as a modulator, or even it could be
linked to another polymorphisms within the same gene as C(-
106)T, for example. Finally, the complex mechanism of the
development of retinal damage, involving at least four differ-
ent metabolic pathways, suggests that we could possibly have
a genotype pattern in our population that leads the Z allele in
the ALR2 gene to become associated with the development of
PDR [27].
One possible source of bias in case-control studies is popu-
lation stratification. The Brazilian population in this particu-
lar set of patients has a high degree of admixture, hindering
accuracy in any attempt to stratify allele frequencies accord-
ing to ethnic backgrounds. However, we have to address that
both the control and the study groups are similar in regard to
ethnical background and geographical distribution. Besides,
allele frequencies for both polymorphisms are in Hardy-
Weinberg equilibrium in the normal control group. The study
design, as well as the sample size, could also interfere with
the results.
In conclusion, this is the first report regarding the investi-
gation of ALR2 promoter polymorphisms in DM1 Brazilian
patients. Two other studies were performed in DM2 Brazilian
patients, evaluating only the C(-106)T substitution. The re-
sults demonstrate an association of the Z allele of the AC(n)
polymorphism, alone or in combination with the C allele of
the C(-106T) polymorphism, with the predisposition to the
development of PDR. This work opens possibilities to further
functional studies in order to confirm the influence of this
genetic change in the susceptibility to diabetic microvascular
complications, which are among the main causes of visual
impairment in the world. This kind of study is also important
to establish the role of genetic factors in the risk of develop-
ing DR, improving the control of the disease.
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